Publications by authors named "Helen McLaughlin"

Article Synopsis
  • Age-related macular degeneration (AMD) is a common cause of vision loss among older adults, and current treatment options are limited.
  • Researchers identified genetic factors contributing to AMD risk by analyzing data from 12,495 AMD cases and 461,686 controls, discovering four key protective haplotypes.
  • The study suggests that lowering levels of the protein FHR-5 could enhance certain immune pathways and potentially serve as a strategy to prevent or treat AMD.
View Article and Find Full Text PDF
Article Synopsis
  • This study investigates how gene-environment interactions (GEIs) affect protein levels in the blood, which could help in discovering and validating new biomarkers.
  • Researchers analyzed blood protein data from over 52,000 UK Biobank participants and identified 677 unique variance quantitative trait loci (vQTLs), which are genetic variations linked to protein levels.
  • The findings reveal over 1,100 GEIs between identified proteins and environmental factors, providing insights into why some genetic variants affect protein levels without obvious main effects, and emphasizing the roles of age, sex, and other factors in genetic variability.
View Article and Find Full Text PDF

CRISPR-based gene editing technology represents a promising approach to deliver therapies for inherited disorders, including amyotrophic lateral sclerosis (ALS). Toxic gain-of-function superoxide dismutase 1 (SOD1) mutations are responsible for ~20% of familial ALS cases. Thus, current clinical strategies to treat SOD1-ALS are designed to lower SOD1 levels.

View Article and Find Full Text PDF

CRISPR-Cas systems have emerged as a powerful tool to generate genetic models for studying normal and diseased central nervous system (CNS). Targeted gene disruption at specific loci has been demonstrated successfully in non-dividing neurons. Despite its simplicity, high specificity and low cost, the efficiency of CRISPR-mediated knockout in vivo can be substantially impacted by many parameters.

View Article and Find Full Text PDF

Study Question: Can the priorities for future research in infertility be identified?

Summary Answer: The top 10 research priorities for the four areas of male infertility, female and unexplained infertility, medically assisted reproduction and ethics, access and organization of care for people with fertility problems were identified.

What Is Known Already: Many fundamental questions regarding the prevention, management and consequences of infertility remain unanswered. This is a barrier to improving the care received by those people with fertility problems.

View Article and Find Full Text PDF

In delayed-release dimethyl fumarate (DMF)-treated patients, absolute lymphocyte count (ALC) often declines in the first year and stabilizes thereafter; early declines have been associated with development of severe prolonged lymphopenia (SPL). Prolonged moderate or severe lymphopenia is a known risk factor for progressive multifocal leukoencephalopathy (PML); DMF-associated PML is very rare. It is unknown whether genetic predictors of SPL secondary to DMF treatment exist.

View Article and Find Full Text PDF

Fibroblasts/myofibroblasts are the key effector cells responsible for excessive extracellular matrix (ECM) deposition and fibrosis progression in both idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc) patient lungs, thus it is critical to understand the transcriptomic and proteomic programs underlying their fibrogenic activity. We conducted the first integrative analysis of the fibrotic programming in these cells at the levels of gene and microRNA (miRNA) expression, as well as deposited ECM protein to gain insights into how fibrotic transcriptional programs culminate in aberrant ECM protein production/deposition. We identified messenger RNA (mRNA), miRNA, and deposited matrisome protein signatures for IPF and SSc fibroblasts obtained from lung transplants using next-generation sequencing and mass spectrometry.

View Article and Find Full Text PDF

A central goal for most biopharmaceutical companies is to reduce the development timeline to reach clinical proof of concept. This objective requires the development of tools that ensure the quality of biotherapeutic material destined for the clinic. Recent advances in high throughput protein analytics provide confidence in our ability to assess productivity and product quality attributes at early stages of cell line development.

View Article and Find Full Text PDF

Purpose: A 30 year-old man with a history of recurrent skin infections as well as elevated serum IgE and eosinophils developed neurological symptoms and had T2-hyperintense lesions observed in cerebral MRI. The immune symptoms were attributed to Hyper IgE syndrome (HIES) and the neurological symptoms with presence of JC virus in cerebrospinal fluid were diagnosed as Progressive Multifocal Leukoencephalopathy (PML). The patient was negative for STAT3 mutations.

View Article and Find Full Text PDF